156 related articles for article (PubMed ID: 38158497)
1. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
Dedeilia A; Lwin T; Li S; Tarantino G; Tunsiricharoengul S; Lawless A; Sharova T; Liu D; Boland GM; Cohen S
Ann Surg Oncol; 2024 Apr; 31(4):2713-2726. PubMed ID: 38158497
[TBL] [Abstract][Full Text] [Related]
2. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
3. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
4. Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients.
Laks S; Meyers MO; Deal AM; Frank JS; Stitzenberg KB; Yeh JJ; Thomas NE; Ollila DW
Am Surg; 2017 Sep; 83(9):972-978. PubMed ID: 28958277
[TBL] [Abstract][Full Text] [Related]
5. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
Tan SY; Najita J; Li X; Strazzulla LC; Dunbar H; Lee MY; Seery VJ; Buchbinder EI; Tawa NE; McDermott DF; Lee SJ; Atkins MB; Kim CC
Melanoma Res; 2019 Feb; 29(1):70-76. PubMed ID: 30169431
[TBL] [Abstract][Full Text] [Related]
8. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
[TBL] [Abstract][Full Text] [Related]
10. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
11. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
[TBL] [Abstract][Full Text] [Related]
13. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
15. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
16. Relapse patterns in patients with local and regional cutaneous melanoma.
Tas F; Erturk K
Clin Transl Oncol; 2019 Apr; 21(4):412-419. PubMed ID: 30182208
[TBL] [Abstract][Full Text] [Related]
17. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
18. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.
Stanelle EJ; Busam KJ; Rich BS; Christison-Lagay ER; Dunkel IJ; Marghoob AA; Halpern A; Coit DG; La Quaglia MP
J Pediatr Surg; 2015 Jun; 50(6):1019-23. PubMed ID: 25819019
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
